Adaptive Biotechnologies (NASDAQ: ADPT) ex-officer plans new share sale

Rhea-AI Filing Summary

Adaptive Biotechnologies Corporation (symbol ADPT) reports that former officer Harlan Robins plans to sell up to 215,632 shares of common stock under Rule 144 through Goldman Sachs & Co. LLC. The filing lists an aggregate market value for these planned sales of $5,496,459.68 and states that there were 159,595,842 shares of common stock outstanding. The securities to be sold were acquired on 03/04/2022 as compensation via stock options, with the planned disposition described as a compensation-related cashless exercise and same-day sale. The notice also details multiple prior sales of ADPT common stock by Robins over the past three months, each with specific share amounts, dates, and dollar values.

Key Figures

Shares to be sold: 215,632 shares Aggregate market value of shares to be sold: $5,496,459.68 Shares outstanding: 159,595,842 shares +5 more

8 metrics

Shares to be sold 215,632 shares Planned Rule 144 sale of Adaptive Biotechnologies common stock

Aggregate market value of shares to be sold $5,496,459.68 Value of 215,632 shares covered by the Form 144 notice

Shares outstanding 159,595,842 shares Adaptive Biotechnologies common stock outstanding as referenced in the notice

Sale on 06/15/2026 100,000 shares; $1,737,460 Common stock sale by Harlan Robins during the past three months

Sale on 07/02/2026 250,000 shares; $5,565,550 Common stock sale by Harlan Robins listed in past three months table

Sale on 08/18/2026 261,044 shares; $6,411,240.64 Most recent common stock sale by Harlan Robins in the three-month history

Acquisition date of option shares 03/04/2022 Date shares to be sold were acquired as compensation via stock options

Approximate sale date 08/19/2026 Approximate date of proposed Rule 144 sale listed in securities information

Key Terms

Rule 144, cashless exercise, same-day sale, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

cashless exercise financial

"Compensation -- Cashless exercise / same-day sale"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

same-day sale financial

"Compensation -- Cashless exercise / same-day sale"

aggregate market value financial

"215632 | 5496459.68 | 159595842 | 08/19/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does the Form 144 filing disclose about ADPT insider Harlan Robins?

The filing discloses that former officer Harlan Robins plans to sell up to 215,632 ADPT shares under Rule 144 through Goldman Sachs & Co. LLC, with detailed information on prior share sales and acquisition via stock options.

How many Adaptive Biotechnologies (ADPT) shares are planned for sale under this Form 144?

The notice covers a planned sale of up to 215,632 shares of ADPT common stock. It also reports an aggregate market value for these shares of $5,496,459.68 in the securities information section.

How were the ADPT shares in this Form 144 acquired by Harlan Robins?

The shares covered by this Form 144 were acquired as compensation on 03/04/2022 through stock options. The planned disposition is described as a compensation -- cashless exercise / same-day sale of Adaptive Biotechnologies common stock.

What prior sales of Adaptive Biotechnologies (ADPT) stock are listed for Harlan Robins?

The filing lists several prior common stock sales by Harlan Robins over the past three months, including 100,000 shares on 06/15/2026, 250,000 shares on 07/02/2026, and 261,044 shares on 08/18/2026, each with associated dollar proceeds.

How many Adaptive Biotechnologies (ADPT) shares were outstanding according to this Form 144?

The securities information section states that 159,595,842 shares of ADPT common stock were outstanding. This figure provides context for the planned Rule 144 sale amount but is not the number of shares being sold.

Who is the broker handling the planned Rule 144 sale for ADPT shares?

The planned sale of 215,632 ADPT shares is to be handled by Goldman Sachs & Co. LLC, listed with its New York address. Goldman Sachs also signs the notice on behalf of Harlan Robins.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 06:28 PM Accepted by SEC EDGAR 08/19/2026 - 06:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001780851
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Adaptive Biotechnologies Corporation
SEC File Number	001-38957
Address of Issuer	1165 Eastlake Avenue East Seattle WASHINGTON 98109
Phone	1-206-659-0067
Name of Person for Whose Account the Securities are To Be Sold	Harlan Robins
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	215632	5496459.68	159595842	08/19/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/04/2022	Acquired as compensation -- Stock Options	The Issuer			215632	03/04/2022	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	06/15/2026	100000	1737460
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	06/16/2026	6160	110945.91
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/02/2026	136240	2936094.62
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/02/2026	250000	5565550
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/21/2026	207600	4538136
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	07/21/2026	284800	6225728
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	08/17/2026	152036	3765931.72
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	08/17/2026	148956	3689640.12
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	08/18/2026	261044	6411240.64

144: Remarks and Signature

Remarks
Date of Notice	08/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Harlan Robins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)